**1. Introduction**

558 Breast Cancer – Focusing Tumor Microenvironment, Stem Cells and Metastasis

[181] Heider U, Kaiser M, Muller C, Jakob C, Zavrski I, Schulz CO, Fleissner C, Hecht M,

[182] Rosen LS 2005 VEGF-targeted therapy: therapeutic potential and recent advances. The

[183] Koutras AK, Fountzilas G, Makatsoris T, Peroukides S, Kalofonos HP 2010

[184] Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, Visvikis A,

[186] Bauerle T, Hilbig H, Bartling S, Kiessling F, Kersten A, Schmitt-Graff A, Kauczor HU,

[187] Addison WN, Azari F, Sorensen ES, Kaartinen MT, McKee MD 2007 Pyrophosphate

[188] Keller MI 2004 Treating osteoporosis in post-menopausal women: a case approach.

[189] Rizzoli R 2011 Bisphosphonates for post-menopausal osteoporosis: are they all the same? QJM : monthly journal of the Association of Physicians 104(4):281-300. [190] Aft R 2011 Bisphosphonates in breast cancer: clinical activity and implications of preclinical data. Clinical advances in hematology & oncology : H&O 9(3):194-205. [191] Sun M, Iqbal J, Singh S, Sun L, Zaidi M 2010 The crossover of bisphosphonates to cancer therapy. Annals of the New York Academy of Sciences 1211:107-12. [192] Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G,

journal of the American Society of Clinical Oncology 23(34):8580-7.

Leukemia Research Fund, U.K 21(9):2025-34.

oncologist 10(6):382-91.

cancer 46(16):3022-36.

and MRI. Neoplasia 10(5):511-20.

Cleveland Clinic journal of medicine 71(10):829-37.

chemistry 282(21):15872-83.

82.

osteoclastogenesis. Leukemia : official journal of the Leukemia Society of America,

Sezer O 2006 Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. European journal of haematology 77(3):233-8.

Bevacizumab in the treatment of breast cancer. Cancer treatment reviews 36(1):75-

Nikolakopoulou A, Acholos V, Karapanagiotidis G, Batziou E, Skarlos DV 2009 Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76(3):209-11. [185] Ortholan C, Durivault J, Hannoun-Levi JM, Guyot M, Bourcier C, Ambrosetti D, Safe S,

Pages G 2010 Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment. European journal of

Delorme S, Berger MR 2008 Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT

inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. The Journal of biological

Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA 2005 Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. Journal of clinical oncology : official The Rho GTPases is a subfamily of molecular switches that cycle between an inactive GDP-bound state and an active GTP-bound state within the Ras superfamily. In the past, members of the Rho subfamily were mainly thought to be involved in the regulation of cytoskeletal organization in response to extracellular growth factors. However, a number of studies over the past few years have revealed that the Rho GTPases play crucial roles in a wide spectrum of cellular functions related to cell adhesion to the extracellular matrix, cell morphology, cell cycle progression, malignant transformation, invasion and metastasis. Alterations of the expression levels to Rho GTPases have been detected in many types of human tumors and, in some cases, up-regulation and/or overexpression of Rho protein correlates with poor prognosis. This article reviews the evidence of aberrant Rho signaling and the cellular effects elicited by Rho GTPases signaling in human breast tumors.
